Aussie Nurses Allegedly Paid To Find Patients For Merck’s Vioxx, Court Told
This article was originally published in PharmAsia News
Australian nurses were allegedly paid by U.S.-based Merck and its Australian subsidiary, Merck, Sharp and Dohme to find prospective patients for the Vioxx (rofecoxib) anti-arthritis drug. That revelation was presented in a continuing class-action suit against the drug maker. The court was told Merck paid the nurses to get a physician's permission to go through his patient records and interview patients about their condition and pain management. Earlier, the court heard that pharmacists were paid by Merck to recommend to patients they take Vioxx instead of other drugs, such as paracetamol. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.